8-K/A: Quanterix Details Akoya Acquisition Pro Forma Financials

Quanterix Corporation filed an amendment to its 8-K report, providing unaudited pro forma financial statements for its recently completed acquisition of Akoya Biosciences, Inc.

Summary

• Quanterix Corporation completed the acquisition of Akoya Biosciences, Inc. on July 8, 2025, pursuant to an Amended and Restated Agreement and Plan of Merger dated April 28, 2025.
• Each Akoya share was converted into 0.1470 shares of Quanterix common stock and $0.37 in cash.
• The total fair value of consideration transferred for the acquisition was $150.196 million, comprising $49.160 million in Quanterix stock, $18.924 million in cash, and $82.101 million for Akoya's debt extinguishment.
• The unaudited pro forma condensed combined financial statements reflect the acquisition using the acquisition method of accounting (ASC 805).
• Pro forma combined total assets as of June 30, 2025, were $464.484 million, with total liabilities of $130.986 million and total stockholders' equity of $333.498 million.
• The acquisition resulted in the preliminary recognition of $31.751 million in goodwill and $85.500 million in identifiable intangible assets.
• Pro forma combined revenue for the six months ended June 30, 2025, was $89.638 million, with a net loss of $74.602 million, or $(1.61) per share.
• Pro forma combined revenue for the year ended December 31, 2024, was $219.093 million, with a net loss of $101.238 million, or $(2.21) per share.
• Non-recurring transaction costs of $8.120 million were accrued by Quanterix related to the merger.

Sentiment

Score: 5

Explanation: The filing is a factual, post-acquisition accounting update providing unaudited pro forma financial statements. It does not contain qualitative statements or performance results that would indicate a positive or negative sentiment, but rather presents a neutral, required disclosure.

Positives

• The acquisition expands Quanterix's operational scale, with pro forma combined annual revenue for 2024 reaching $219.093 million.
• The combined entity's total assets are projected to be $464.484 million as of June 30, 2025, indicating a larger asset base.
• The recognition of $85.500 million in identifiable intangible assets, including developed technology and in-process research & development, suggests potential for future innovation and market position.

Negatives

• The pro forma combined net loss for the six months ended June 30, 2025, was $(74.602) million, and for the year ended December 31, 2024, was $(101.238) million, indicating significant combined losses.
• The pro forma net loss per common share was $(1.61) for the six months ended June 30, 2025, and $(2.21) for the year ended December 31, 2024.
• Quanterix incurred $8.120 million in non-recurring transaction costs related to the merger.
• The pro forma financial statements do not reflect the cost of any integration activities, cost savings from synergies, or cost increases from dis-synergies, which could further impact future results.

Risks

• The unaudited pro forma financial statements are based on preliminary estimates and assumptions, and the final amounts recorded for assets acquired and liabilities assumed may differ materially.
• Quanterix is still reviewing Akoya's accounting policies, and additional differences could be identified, potentially having a material impact on the financial information.
• The pro forma financial information is for illustrative purposes only and is not necessarily indicative of the financial position or results of earnings that would have been realized if the Merger had been completed on the dates set forth, nor is it indicative of future results or financial position.
• A 10% change in the valuation of intangible assets would cause a corresponding increase or decrease to goodwill and a resulting increase or decrease in amortization expense of approximately $611 thousand for the six months ended June 30, 2025, and $1,221 thousand for the year ended December 31, 2024.

Future Outlook

The unaudited pro forma condensed combined financial statements are for illustrative purposes only and are not necessarily indicative of the financial position or results of earnings that would have been realized if the Merger had been completed on the dates set forth, nor are they indicative of future results or financial position. They do not reflect the cost of any integration activities, cost savings from synergies, or cost increases from dis-synergies.

Stakeholder Impact

• Shareholders of Quanterix: Experience dilution from new shares issued and potential long-term value from the strategic acquisition, but also bear the combined entity's losses and integration risks.
• Shareholders of Akoya: Received a combination of Quanterix stock and cash for their shares.
• Employees: Akoya employees are now part of the combined Quanterix organization, subject to integration processes.
• Customers: The combined entity aims to offer a broader portfolio of products and services.

Key Dates

Keywords

Quanterix Corporation, Akoya Biosciences, Acquisition, Merger, Pro Forma Financials, SEC Filing, 8-K/A, Business Combination, Financial Reporting, Biotechnology, Life Sciences, Diagnostics, QTRX